Bayer's Asundexian Approved by NMPA to Reduce Stroke Risk in Adults with Ischemic Stroke or High-Risk TIA

Bayer's asundexian (brand name Shuhuabo) has been approved by China's NMPA to reduce stroke risk in adults with ischemic stroke or high-risk TIA, excluding patients with cardioembolic stroke. The original article says that as a Factor XIa inhibitor, asundexian can in theory reduce clot formation and thereby lower the risk of vessel narrowing or blockage without markedly raising the risk of major bleeding. In 2026, filings were launched in China, the United States and Japan, with China approving it first.